Le Lézard
Classified in: Health, Science and technology
Subjects: Conference, Trade Show

ALX Oncology to Present ALX148 Clinical Data at the 61st American Society of Hematology Annual Meeting (ASH)


ALX Oncology, a clinical-stage immuno-oncology company developing therapies to block the CD47 checkpoint mechanism, today announced that ALX148 clinical results have been selected for presentation at the 61st ASH Annual Meeting & Exposition, December 7 ? 10, 2019, Orange County Convention Center, Orlando, FL.

"This year's ASH meeting will be an opportunity to provide important clinical updates on our CD47 program in hematologic malignancies," said Sophia Randolph M.D., Ph.D., Chief Medical Officer of ALX Oncology. "We are excited to share the first clinical efficacy data from the combination of ALX148 with rituximab, showing that ALX148 maximizes clinical activity with a best-in-class safety profile. We are committed to further development of this agent with the potential to transform standards-of-care for patients with cancer."

Abstract Details
The presentation will include updated clinical data from the ongoing phase 1b study of ALX148, administered up to 15 mg/kg once weekly (molar equivalent to 30 mg/kg once weekly of an antibody), in combination with rituximab in patients with relapsed/refractory non-Hodgkin lymphoma.

Title: A Phase 1 Study of ALX148, a CD47 Blocker, in Combination with Rituximab in Patients with Non-Hodgkin Lymphoma
Session Name: 704. Immunotherapies: Poster I
Session Date: Saturday, December 7, 2019
Presentation Time: 5:30pm ? 7:30pm
Location: Orange County Convention Center, Hall B
Publication Number: 1953

About ALX Oncology
ALX Oncology is a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint mechanism, which is exploited by cancer cells to evade the immune system. Our lead candidate, ALX148, is a first-in-class fusion protein comprised of an engineered high affinity CD47 binding domain of SIRP? linked to an inactive Fc region of human immunoglobulin. ALX148 is designed to maximize the clinical benefit of antibody-based therapies and is in clinical development for a broad range of tumor types. For more information about the Phase 1 study, please visit clinicaltrials.gov, identifier number NCT03013218.
www.alxoncology.com


These press releases may also interest you

at 10:00
White Knight Press has just released Photographer's Guide to the Nikon Coolpix P950, a full-color, detailed guide book covering the menus, features, controls, and operation of the Nikon Coolpix P950 superzoom camera. This book, by Alexander S. White,...

at 08:05
Incyte today announced the first presentation of Phase 3 data for ruxolitinib cream in atopic dermatitis at the Revolutionizing Atopic Dermatitis Virtual Symposium. The Phase 3 TRuE-AD program, which includes the TRuE-AD1 and TRuE-AD2 studies, is...

at 08:00
As people in America and around the world continue to practice safety within their homes; in an effort to control the spread of this virus we present to you a Def Comedy Jam in support of communities in need during this COVID-19 Public Health Crisis,...

at 07:00
Plataine, a leading provider of Industrial IoT (IIoT) and AI-based software for advanced manufacturing optimization, is excited to announce that it joined the membership network of The National Composites Centre (NCC), the UK research center...

4 avr 2020
Womply, a software and API company serving small businesses and app developers, today announced that it is helping American small businesses get faster access to Paycheck Protection Program loans as a verified loan agent for multiple SBA 7(a)...

4 avr 2020
Ex-Formula 1 stars Rubens Barrichello and Jan Magnussen plus esports racer Kevin Siggy were the big winners in today's Legends Trophy esports races and The Race All-Star Cup - Fully Charged by ROKiT Phones. The...



News published on 14 november 2019 at 07:05 and distributed by: